05.07.2012 - Under its FP7 programme, the EU will fund a project with the aim to develop a new blood apheresis device for in vivo trapping of circulating tumour cells (CTC).
The consortium of eleven companies, universities, and research institutes is coordinated by Leon Terstappen, Professor of Medical Cell Biophysics at the University of Twente (MIRA Institute, Netherlands). CTCs detach from a primary tumour and circulate in the bloodstream. They play a crucial role in spreading tumour tissue around a patient’s body. Currently only a small quantity of CTCs can be isolated from blood sample volumes of 7.5 mL for genetic and immune phenotyping to assess the sensitivity of tumour cells towards certain therapeutics. The development project totals EUR9m, of which EUR6m are provided by the EU grant. The German specialist Leukocare will develop an extracorporeal blood apheresis column to filter the patient’s whole blood stream under the roof of the programme. This in vivo trapping will increase the sensitivity of cell counting by about 500-fold. Leukocare will receive a EUR 810,000 contribution from the grant over a period of two years to fund its developmental research.
16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.
10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.
05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.
03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.